20/20 GeneSystems
Diagnostic Testing for COVID-19 & Cancer
Overview
Raised: $232,704
Total Commitments ($USD)
StartEngine
08/15/2022
12/21/2022
$500
Convertible Note
Series A
RegCF
$58,400,000
10%
Rolling Commitments ($USD)
12/30/2022
$1,832
160
2000
Healthcare & Pharmaceuticals
HealthTech
B2B/B2C
Medium
High
Summary Profit and Loss Statement
| Most Recent Year | Prior Year | |
|---|---|---|
|
Revenue |
$9,622,332 |
$2,330,528 |
|
COGS |
$4,927,374 |
$1,453,354 |
|
Tax |
$0 |
$0 |
| ||
| ||
|
Net Income |
$2,071,777 |
$-2,021,826 |
Summary Balance Sheet
| Most Recent Year | Prior Year | |
|---|---|---|
|
Cash |
$3,354,469 |
$3,468,192 |
|
Accounts Receivable |
$4,215,465 |
$205,071 |
|
Total Assets |
$10,272,281 |
$4,677,734 |
|
Short-Term Debt |
$0 |
$103,860 |
|
Long-Term Debt |
$0 |
$40,247 |
|
Total Liabilities |
$0 |
$144,107 |
Raise History
| Offering Name | Close Date | Platform | Valuation/Cap | Total Raised | Security Type | Status | Reg Type |
|---|---|---|---|---|---|---|---|
| 20/20 GeneSystems | 12/20/2022 | StartEngine | $58,400,000 | $232,704 | Convertible Note | Funded | RegCF |
| 20/20 GeneSystems | 06/26/2021 | StartEngine | $38,500,000 | $2,903,017 | Equity - Preferred | Funded | RegA+ |
| 20/20 GeneSystems | 10/31/2020 | SeedInvest | $38,500,000 | $3,792,229 | Equity - Preferred | Funded | RegA+ |
| 20/20 GeneSystems | 12/13/2017 | Microventures | $23,000,000 | $1,064,807 | Equity - Preferred | Funded | RegCF |
Price per Share History
Note: Share prices shown in earlier rounds may not be indicative of any stock splits.
Valuation History
Revenue History
Note: Revenue data points reflect the latest of either the most recent fiscal year's financials, or updated revenues directly from the founder, at each raise's close date.
Employee History
Upgrade to gain access
-
$25 /month
billed annually - Free portfolio tracking, data-driven ratings, AI analysis and reports
- Plan Includes:
- Everything in Free, plus
- Company specific
KingsCrowd ratings and analyst reports
- Deal explorer and side-by-side comparison
- Startup exit and failure tracking
- Startup market filters and historical industry data
- Advanced company search ( with ratings)
- Get Edge Annual
Edge
Ratings 
Analyst Report
20/20 GeneSystems offers an affordable blood test that screens for multiple types of cancer. It also has access to the medical records of more than 200,000 patients with known cancer outcomes. Its testing technology and machine learning algorithms are innovative — but it’s not clear if there’s enough market demand for its product.